3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
108
INDUSTRY
51
NIH
34
OTHER_GOV
5
NETWORK
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
19
Lymphoid
3
Myeloid
2
Sarcoma
1
Plasma cell
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Conditions
Multiple Myeloma
93
Neoplasms, Plasma Cell
22
Immunoglobulin Light-chain Amyloidosis
19
Waldenstrom Macroglobulinemia
10
Lymphoma, Non-Hodgkin
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Recurrence
8
Monoclonal Gammopathy of Undetermined Significance
8
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
8
Lymphoma, B-Cell, Marginal Zone
8
Burkitt Lymphoma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Mantle-Cell
7
Lymphoma
7
Leukemia, Myeloid, Acute
7
Hodgkin Disease
7
Thrombocythemia, Essential
6
Primary Myelofibrosis
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Polycythemia Vera
6
Pdgfra-Associated Chronic Eosinophilic Leukemia
6
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, Large-Cell, Anaplastic
6
Leukemia, Neutrophilic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid, Accelerated Phase
6
Leukemia, Hairy Cell
6
Blast Crisis
6
Interventions
Sirolimus
1
Lenalidomide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Hematologic Neoplasms
×
Plasma cell
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled